AlzeCure’s ACD856 Demonstrates Good Tolerability in Phase I Clinical Trial and is Approved for Additional Doses

STOCKHOLM, SWEDEN / ACCESSWIRE / August 27, 2021 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6)AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of candidate drugs for diseases affecting the central …